Indeed, in human lymphocytes, A2AR agonist inhibits the release of proinflammatory cytokines, cell proliferation, the expression of the adhesion molecule VLA-4, and the activation of the transcription factor NF-κB; these effects were more evident in lymphocytes from MS patients in comparison to healthy subjects, in line with upregulation of A2ARs in MS lymphocytes (Vincenzi et al., 2013). The gene discussed is NFKB1; the disease is myeloid sarcoma.